Walvax Shares Vaccine Development Expertise at 11th National Vaccine Conference of Thailand
(November 15, 2024, Bangkok) - Walvax Biotechnology Co., Ltd. ("Walvax", together with its subsidiaries, the "Group", stock code: 300142.SZ), a leading bio-pharmaceutical company in China, participated in the prestigious 11th National Vaccine Conference of Thailand, demonstrating its commitment to advancing global vaccine development and manufacturing capabilities. The conference, held from November 13-15 at The Berkeley Hotel Pratunam in Bangkok, brought together international vaccine experts under the theme "Vaccines for a Borderless World."
Her Royal Highness Princess Maha Chakri Sirindhorn presided over the conference's opening ceremony and presented the Vaccine Contribution Award to Prof. Dr. Kulkanaya Chokpaiboonkit, Faculty of Medicine Siriraj Hospital, Mahidol University. The conference addressed critical topics including Thailand Preparedness for Emerging and Re-emerging Diseases, Strengthening Vaccine Capacity in Asia, Challenges of Building Resilience in Immunization Programme in a Borderless World, etc.
Dr. Xin Tong, General Manager of R&D and Translational Center of Walvax, was invited to participate a panel discussion focused on "Accelerating Vaccine Development and Manufacturing by Collaborating among Different Partners." During his presentation, Dr. Tong highlighted two successful local production cases from Walvax's portfolio, demonstrating the company's proven track record in technology transfer. This session was part of the conference's key focus area on strengthening vaccine capacity in Asia. "The conference provided an excellent platform for sharing insights and fostering international collaboration in vaccine development," said Dr. Xin Tong.
The event featured prominent healthcare leaders including Dr. Nakorn Premsri, Director of the National Vaccine Institute (NVI); Prof. Emeritus Piyasakol Sakolsatayadorn, Advisor to The National Committee for Emerging Infectious Disease Preparedness; Dr. Niteen Wairagkar, World Economic Forum/Africa Vaccine Manufacturing/CEPI Consultant; Dr. Frederik Kristensen, RVMC Managing Director; Dr. Jerome Kim, IVI Director General, along with hundreds of distinguished pediatricians and medical students from leading universities.
About Walvax
Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Headquartered in China's southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from conventional vaccines to innovative vaccines. Walvax's purpose is to help everyone live a healthy life and has delivered vaccine products to 21 countries. For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.